Key references: Considerations for systemic MHT in premature ovarian insufficiency or early menopause

Baber RJ, Panay N, Fenton AGroup IMSW. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016;19(2):109–50. https://www.ncbi.nlm.nih.gov/pubmed/26872610
Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 2012;13(11):1141–51. https://www.ncbi.nlm.nih.gov/pubmed/23084519
Gazarra LBC, Bonacordi CL, Yela DA, Benetti-Pinto CL. Bone mass in women with premature ovarian insufficiency: a comparative study between hormone therapy and combined oral contraceptives. Menopause 2020. https://www.ncbi.nlm.nih.gov/pubmed/32576798
POI Guideline Development Group. Management of women with premature ovarian insufficiency. Guideline of the European Society of Human Reproduction and Embryology (ESHRE). Grimbergen, Belgium: ESHRE; 2015. https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Management-of-premature-ovarian-insufficiency.aspx
Xu X, Jones M, Mishra GD. Age at natural menopause and development of chronic conditions and multimorbidity: results from an Australian prospective cohort. Hum Reprod 2020;35(1):203–11. https://www.ncbi.nlm.nih.gov/pubmed/31955198